Tesamorelin is a synthetic 44-residue peptide amide modelled on endogenous human growth hormone-releasing hormone (GHRH 1–44) and known in the early research literature as TH9507 (CAS 218949-48-5). Its signature is a trans-3-hexenoyl acylation at the N-terminal tyrosine, the structural change that separates it from native GHRH. This entry supplies a 2 mg lyophilised vial — a lower-strength format that suits pilot experiments, method scouting, or laboratories validating a protocol before scaling to larger fills.
Preclinical research has characterised tesamorelin as an agonist at the growth hormone-releasing hormone receptor (GHRHR) found on anterior-pituitary somatotrophs. Studies have traced how this binding activates the cAMP/PKA signalling route and prompts pulsatile release of endogenous growth hormone (GH), which is why the peptide is often used as a controlled probe of the hypothalamic-pituitary-somatotropic axis. Endocrinology journals have additionally documented its use in metabolic and adipose-tissue research settings.
Chemically, tesamorelin corresponds to the formula C₂₂₁H₃₆₆N₇₂O₆₇S and an approximate molecular weight of 5,135.87 Da. The N-terminal trans-3-hexenoic acid group is notable for conferring resistance to dipeptidyl peptidase-4 (DPP-4) degradation — a property that helps preserve peptide integrity even in the small-volume reconstitutions typical of a 2 mg vial.
Core Power Peptides supplies this 2 mg tesamorelin at a minimum purity of 99%+, verified through HPLC and mass spectrometry and lyophilised under sterile conditions. Every batch is third-party tested, with a certificate of analysis available on request.
Storage: Store lyophilised tesamorelin at −20°C for long-term preservation. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days, keeping the vial away from direct light and repeated freeze-thaw cycles.
This product is intended strictly for in vitro and laboratory research use only. It is not approved for human consumption or therapeutic application, and no medical or clinical claims are made.
